Schering Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Schering Pharma Ag

Schering Aktiengessellschaft

Judi Bryant

Shendong Yuan

Brad Owen Buckman

Imadul Islam

Raju Mohan

Wei Xu

Michael M Morrissey

Guo Ping Wei

Monica J Kochanny

Christopher West

Gary Bruce Phillips

Damian O Arnaiz

Richard L Feldman

Karen B May

Yuo-Ling Chou

Wheeseong Lee

Seock-Kyu Khim

Paul Hrvatin

Kumar Emayan

Hans Briem

Dirk Kosemund

Joachim Kuhnke

Bin Ye

Martin Krueger

Peter Esperling

Lars Wortmann

Marc Adler

Christoph Huwe

Stefan Baeurle

Ulf Bomer

Emil Eckle

Robert Guo-Ping Wei

Mark Polokoff

Hongyi Yu

Victor Selchau

Janet Meurer Ogden

Michael Mamounas

Michael Morrissey

This invention provides novel dihydropyridine derivatives of the formula I having protein tyrosine kinase inhibitory activity, to process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions.

Dihydropyridine derivatives as useful as protein kinase inhibitors

Compounds of the following formula (I), for example: wherein R, R, R, and Rare described herein, are useful as inhibitors of plasma carboxypeptidase B. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

Plasma carboxypeptidase B inhibitors

Compounds of the following formula (I), for example: (1), wherein R, R, R, and Rare described herein, are useful as inhibitors of plasma carboxypeptidase B. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein. 

This invention relates to pyrimidine derivatives of general formula (I) as inhibitors of kinases, their production as well as their use as medications for treating various diseases.

Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents

Compounds of the following formula (I): where A, a, b, R, R, R, Rand Rare described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

Platelet adenosine diphosphate receptor antagonists

Indolinone derivatives, such as compounds of the formula (I): 

Indolinone derivatives and their use in treating disease-states such as cancer

Compounds of the following formula: where m, n, R, R, R, Rand Rare described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

Compounds of the following formula (I):where a, b, R, R, R, Rand Rare described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

Growing community of inventors

Mill Valley, CA, United States of America

Judi Bryant